Trial Profile
Phase I Study of the Activity and Safety of Lenalidomide and Rituximab as Non-chemotherapy Therapy for Patients With Recurrent and Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
- 27 Sep 2013 Trial phase changed from I/II to I and official title amended as reported by ClinicalTrials.gov.
- 27 Sep 2013 Trial phase changed from I/II to I and official title amended as reported by ClinicalTrials.gov.